Phase 2 N=49 Staccato Alprazolam in Panic Attack
Treatment of Induced Panic Attack
Primary: Number of Participants With Doxapram-induced Panic Attack — 14; 9 Participants — p=0.200
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=53 LUCHAR - Latinos Using Counseling for Help With Asthma and Anxiety Reduction
Asthma · Panic Disorder
Primary: Change in Severity of Panic Disorder as Measured by the Panic Disorder Severity Scale — 2.17; 2.40; 1.64; 1.52 score on a scale
Phase 4 N=183 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
Depression · Generalized Anxiety Disorder · Panic Disorder
Primary: Change in Mental Health-related Quality of Life From Baseline to 24 Weeks — 8.87; 8.39 units on a scale — p=0.002
Early Phase 1 N=53 Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine
Nicotine Addiction · Panic Attack
Primary: Smoking Abstinence — 8.25; 12.35 percentage of participants
Phase 3 N=3,489 A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Acute Coronary Syndrome
Primary: Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 — 123; 139; 34; 31 Participants — p=0.238
Phase 2 N=25 Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression
Panic Disorder · Major Depressive Disorder
Primary: Panic Disorder Severity Scale (PDSS) — 6; 1 responders
Phase 4 N=26 A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients
Panic Disorder
Primary: Change in Mean Total Panic Disorder Severity Scale (PDSS) Scores — -5.3; -5.6 units on a scale
N/A N=77 Internet-based Self-help Treatment for Panic Disorder: Two Ways of Complementary Psychological Support
Panic Disorder
Primary: Change From Baseline Score in the Panic Disorder Severity Scale at 8 Weeks and 6 Months. — 15.29; 15.75; 13.08; 10.42 units on a scale (range= 0-28) — p=0.05
Phase 4 N=3 The Role of Orexin in Human Panic Disorder
Panic Disorder
Primary: Change in Orexin Levels (Blood) +1 Minute
N/A N=105 Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion
ST Elevation Myocardial Infarction
Primary: Index of Microcirculatory Resistance — 24.8; 45.0 units
Phase 2 N=87 Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
Left Ventricular Dysfunction
Primary: Global Left Ventricular Function — 0.5; 3.6 percentage of ejection fraction — p=<0.05
Phase 3 N=302 Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial
Acute Coronary Syndrome
Primary: 7-Day Point Prevalence Smoking Abstinence — 70; 49 Participants
N/A N=200 Novel Biomarkers of Thrombotic Risk
Myocardial Infarction
Primary: Cardiovascular Event - Myocardial Infarction, Stroke, Death — 17; 6 Participants — p=0.007
Phase 1 N=20 A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms
Healthy
Primary: Maximum Change From Baseline in Panic Symptom Scale (PSS) Sum Intensity Score — 22.639; 29.944 Score on a scale
Phase 4 N=1,302 Study of Adacel® Vaccine Administered to Persons 10 Years of Age
Tetanus · Diphtheria · Pertussis
Primary: Summary of Geometric Mean Titers of Anti-Pertussis Titers Following a Single Dose of Adacel® Vaccine — 30.1; 32.0; 232; 225 Titers (1/dilutions)